tetano
Editor, Senior Moderator
Int Immunopharmacol
. 2021 Jul 23;99:107998.
doi: 10.1016/j.intimp.2021.107998. Online ahead of print.
IgM-enriched immunoglobulin in COVID-19: Case series of 15 severely ill SARS-CoV-2-infected patients
Payam Tabarsi[SUP] 1 [/SUP], Seyed Mohammad Reza Hashemian[SUP] 2 [/SUP], Artur Bauhofer[SUP] 3 [/SUP], Ali Amir Savadkoohi[SUP] 4 [/SUP], Somayeh Ghadimi[SUP] 1 [/SUP], Sara Haseli[SUP] 2 [/SUP], Farzaneh Dastan[SUP] 5 [/SUP]
Affiliations
Abstract
The healthcare system in Iran, like most around the world, is managing thousands of patients hospitalised with COVID-19. In Iran, in-hospital mortality is in the region of 25%, rising to 50-60% in patients admitted to intensive care. Hyperinflammation, characterised by cytokine storm, appears to be a hallmark of severe COVID-19 and to date only the anti-inflammatory drug dexamethasone has been shown to reduce mortality in those hospitalised with the disease. There is a sound scientific rationale behind the use of IgM-enriched immunoglobulin in the management of patients with severe COVID-19. It has been used successfully in the management of hyperinflammation in patients with sepsis and has led to improved radiographic scores in patients with severe cases of severe acute respiratory syndrome coronavirus (SARS-CoV) infection. Recently the successful treatment of a patient with COVID-19 with IgM-enriched immunoglobulin was reported. Here we report the outcome of a further 15 patients hospitalised with COVID-19 treated with IgM-enriched immunoglobulin. Improvements in computed tomography (CT) score were observed in nine patients, indicating that further clinical studies into the use of IgM-enriched immunoglobulin in the treatment of severe COVID-19 are warranted.
Keywords: COVID-19; Cytokine storm; Hyperinflammation; IgM-enriched immunoglobulin; Intravenous immunoglobulin (IVIG); SARS-CoV-2.
. 2021 Jul 23;99:107998.
doi: 10.1016/j.intimp.2021.107998. Online ahead of print.
IgM-enriched immunoglobulin in COVID-19: Case series of 15 severely ill SARS-CoV-2-infected patients
Payam Tabarsi[SUP] 1 [/SUP], Seyed Mohammad Reza Hashemian[SUP] 2 [/SUP], Artur Bauhofer[SUP] 3 [/SUP], Ali Amir Savadkoohi[SUP] 4 [/SUP], Somayeh Ghadimi[SUP] 1 [/SUP], Sara Haseli[SUP] 2 [/SUP], Farzaneh Dastan[SUP] 5 [/SUP]
Affiliations
- PMID: 34315117
- DOI: 10.1016/j.intimp.2021.107998
Abstract
The healthcare system in Iran, like most around the world, is managing thousands of patients hospitalised with COVID-19. In Iran, in-hospital mortality is in the region of 25%, rising to 50-60% in patients admitted to intensive care. Hyperinflammation, characterised by cytokine storm, appears to be a hallmark of severe COVID-19 and to date only the anti-inflammatory drug dexamethasone has been shown to reduce mortality in those hospitalised with the disease. There is a sound scientific rationale behind the use of IgM-enriched immunoglobulin in the management of patients with severe COVID-19. It has been used successfully in the management of hyperinflammation in patients with sepsis and has led to improved radiographic scores in patients with severe cases of severe acute respiratory syndrome coronavirus (SARS-CoV) infection. Recently the successful treatment of a patient with COVID-19 with IgM-enriched immunoglobulin was reported. Here we report the outcome of a further 15 patients hospitalised with COVID-19 treated with IgM-enriched immunoglobulin. Improvements in computed tomography (CT) score were observed in nine patients, indicating that further clinical studies into the use of IgM-enriched immunoglobulin in the treatment of severe COVID-19 are warranted.
Keywords: COVID-19; Cytokine storm; Hyperinflammation; IgM-enriched immunoglobulin; Intravenous immunoglobulin (IVIG); SARS-CoV-2.